<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370851</url>
  </required_header>
  <id_info>
    <org_study_id>8532</org_study_id>
    <nct_id>NCT00370851</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial</brief_title>
  <official_title>Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      In this study we intend to evaluate the outcome of intravitreal avastin on improving the
      visual acuity and macular edema and late complications of BRVO like NVD and NVE
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After diabetic retinopathy, vein occlusion is the second most common retinovascular disease.
      According to BVO study the only effective management of it is macular photocoagulation for
      macular thickening that persist after 3 months.But we may miss a golden time which resulted
      to photoreceptor degeneration due to macular edema during this period. VEGF inhibitors newly
      have been shown that may be effective on a wide range of retinovascular diseases that
      resulted to macular edema or new vessels formation. In this study we aim to show the outcomes
      of one of this VEGF inhibitors (bevacizumab) on complications of BRVO in a sham controlled
      clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>At 12 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Macular thickness by OCT</measure>
    <time_frame>At 12 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for macular photocuagulation</measure>
    <time_frame>At 12th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new vessel formation</measure>
    <time_frame>At 12th week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Retinal Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of Avastin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin (Bevacizumab)</intervention_name>
    <description>Intravitreal injection of 125 mg Avastin</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with acute BRVO with less than three month duration

        Exclusion Criteria:

          -  vision less than 20/320 and vison more than 20/50

          -  duration more than 3 months

          -  history of glaucoma and diabetic retinopathy

          -  any media opacity that prevent funduscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siamak Moradian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Research Center of Shaheed Beheshti Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Siamak Moradian, MD</name>
      <address>
        <city>Tehran</city>
        <zip>16666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2006</study_first_submitted>
  <study_first_submitted_qc>August 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2006</study_first_posted>
  <last_update_submitted>November 23, 2009</last_update_submitted>
  <last_update_submitted_qc>November 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2009</last_update_posted>
  <keyword>intravitreal Avastin</keyword>
  <keyword>BRVO</keyword>
  <keyword>Macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

